Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 158

Sort by

Sort Order Select

Journal Articles

Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations

Blood (2025) 146 (23): 2821–2832.

https://doi.org/10.1182/blood.2025030259

Published: 2025

Includes: Supplemental data

Journal Articles

Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678

Ariel Leyte-Vidal, Ian Outhwaite, Kaeli Miller, Emma Gebauer, Ailin Alvarez, Carlyn Leavitt, Nellie Ahmadieh, Brian Farrell, Isabelle Kwan, Susan Branford, Muneeza Maqsood, David Yeung, Timothy Hughes, Vivian Oehler, Delphine Rea, Ralf Landgraf, Ivette Bahar, Markus Seeliger, Neil Shah

Blood (2025) 146 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2025-1516

Published: 2025

Journal Articles

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Blood (2025) 146 (Supplement 1): 75.

https://doi.org/10.1182/blood-2025-75

Published: 2025

Journal Articles

A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation

Vaidehi Krishnan, Xi Ren, Kian Leong Lee, Radhika Sonthalia, Prasanna Venkatesh, Mengge Yu, Pavithra Shyamsunder, John Ouyang, Xinyi Yang, Florian Schmidt, Verity Saunders, Naranie Shanmuganathan, Charles Chuah, Naoto Takahashi, Susan Branford, Timothy Hughes, Shyam Prabhakar, Sin Tiong Ong

Blood (2025) 146 (Supplement 1): 74.

https://doi.org/10.1182/blood-2025-74

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia

Naranie Shanmuganathan, Susan Branford, David Yeung, David Ross, Timothy Hughes

Blood (2025) 146 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2025-2008

Published: 2025

Journal Articles

Whole genome sequencing reveals that the Philadelphia chromosome (Ph) can evolve and gain complex chromoplectic sequence rearrangements associated with tyrosine kinase inhibitor (TKI) resistance

Susan Branford, Carol Wadham, Nur Hezrin Shahrin, Verity Saunders, Rosalie Kenyon, Ming Lin, Dominic Kaczorowski, Muneeza Maqsood, Hamish Scott, John Toubia, Naranie Shanmuganathan, Chung Kok, Timothy Hughes

Blood (2025) 146 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2025-3770

Published: 2025

Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Blood (2024) 144 (19): 1993–2001.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1 , and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors

Naranie Shanmuganathan, Carol Wadham, David T Yeung, Nur Hezrin Shahrin, Adelina Fernandes, Muneeza Maqsood, Chung Hoow Kok, Verity A Saunders, Ilaria Stefania Pagani, Rosalie Kenyon, Ming Lin, David M Ross, Timothy P Hughes, Susan Branford

Blood (2024) 144 (Supplement 1): 991.

https://doi.org/10.1182/blood-2024-199899

Published: 2024

Journal Articles

Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure

Susan Branford, Adelina Fernandes, Carol Wadham, Muneeza Maqsood, Nur Hezrin Shahrin, David M Ross, Agnes S. M. Yong, Ming Lin, Rosalie Kenyon, Dominik Kaczorowski, Verity A Saunders, Ilaria Stefania Pagani, John Toubia, Joe McConnell, David T Yeung, Chung Hoow Kok, Timothy P Hughes, Naranie Shanmuganathan

Blood (2024) 144 (Supplement 1): 996.

https://doi.org/10.1182/blood-2024-198827

Published: 2024

Journal Articles

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Blood (2024) 144 (Supplement 1): 476.

https://doi.org/10.1182/blood-2024-201218

Published: 2024

Journal Articles

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Ilaria Stefania Pagani, Vaidehi Krishnan, John Ouyang, Chung How Kok, BeiJun Chen, Elyse C Page, Phuong Dang, Verity A Saunders, Jane James, Kelly Lim, Naranie Shanmuganathan, Susan Branford, Charles Chuah, David T Yeung, Daniel Thomas, Timothy P Hughes, Sin Tiong Ong, David M Ross

Blood (2024) 144 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2024-206591

Published: 2024

Journal Articles

Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant

Gauri Wechalekar, Alia Cibich, Monika Kutyna, Naranie Shanmuganathan, Usha Chandra Sekaran, Deepak Singhal, Ashanka Mahilal Beligaswatte, Leanne Purins, Christopher N. Hahn, David T Yeung, Peter Bardy, Duncan Purtill, Ashish Bajel, Susan Branford, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 4928.

https://doi.org/10.1182/blood-2024-209049

Published: 2024

Journal Articles

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Blood (2024) 144 (Supplement 1): 993.

https://doi.org/10.1182/blood-2024-201881

Published: 2024

Journal Articles

Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

Jiarna R. Zerella, Claire C. Homan, Peer Arts, Xuzhu Lin, Sam J. Spinelli, Parvathy Venugopal, Milena Babic, Peter J. Brautigan, Lynda Truong, Luis Arriola-Martinez, Sarah Moore, Rachel Hollins, Wendy T. Parker, Hung Nguyen, Karin S. Kassahn, Susan Branford, Simone Feurstein, Lise Larcher, Flore Sicre de Fontbrune, Serwet Demirdas, Sonja de Munnik, Hélène Antoine-Poirel, Benedicte Brichard, Sahar Mansour, Kristiana Gordon, Marcin W. Wlodarski, Ashwin Koppayi, Sara Dobbins, Pim G. N. J. Mutsaers, Kim E. Nichols, Ninad Oak, Desiree DeMille, Rong Mao, Ali Crawford, Julie McCarrier, Donald Basel, Josue Flores-Daboub, Michael W. Drazer, Kerry Phillips, Nicola K. Poplawski, Graeme M. Birdsey, Daniela Pirri, Pia Ostergaard, Annet Simons, Lucy A. Godley, David M. Ross, Devendra K. Hiwase, Jean Soulier, Anna L. Brown, Catherine L. Carmichael, Hamish S. Scott, Christopher N. Hahn

Blood (2024) 144 (17): 1765–1780.

https://doi.org/10.1182/blood.2024024607

Published: 2024

Includes: Supplemental data

Journal Articles

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Blood (2024) 143 (18): 1873–1877.

https://doi.org/10.1182/blood.2023023593

Published: 2024

Includes: Supplemental data

Journal Articles

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Ilaria S. Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A. Saunders, Randall Grose, Chung H. Kok, Jane James, Molly Tolland, Jodi A. Braley, Haley K. Altamura, David T. Yeung, Susan Branford, Agnes S. M. Yong, Timothy P. Hughes, David M. Ross

Blood (2023) 142 (25): 2192–2197.

https://doi.org/10.1182/blood.2023021119

Published: 2023

Includes: Supplemental data

Journal Articles

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Susan Branford, Carol Wadham, Naranie Shanmuganathan, Adelina Fernandes, Nur Hezrin Shahrin, Jinghua Feng, John Toubia, Paul Wang, Chung Hoow Kok, Muneeza Maqsood, Verity Saunders, Rob King, Ming Lin, Rosalie Kenyon, Ilaria Stefania Pagani, David T Yeung, David M. Ross, Agnes S. M. Yong, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 447.

https://doi.org/10.1182/blood-2023-174425

Published: 2023

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial

Susan Branford, Andreas Hochhaus, Michael Mauro, Yosuke Minami, Delphine Rea, Carla Maria Boquimpani De Moura Freitas, Pablo Serrano-Fernandez, Vanessa Obourn, Andreas Bruederle, Noemi Espurz, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 449.

https://doi.org/10.1182/blood-2023-187636

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations

Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation

Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia

Whole genome sequencing reveals that the Philadelphia chromosome (Ph) can evolve and gain complex chromoplectic sequence rearrangements associated with tyrosine kinase inhibitor (TKI) resistance

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1 , and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors

Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only